Mounjaro and Zepbound are the same molecule. So what's different?

Here is the short answer: Mounjaro and Zepbound contain the same active ingredient, tirzepatide, and both are made by Eli Lilly [1, 2]. The difference is not the molecule. It is what each brand is FDA-approved to treat, and that one difference shapes insurance coverage, cost, and which name ends up on a prescription.

This article explains why one molecule carries two brand names, what matches and what does not, and how coverage and pricing differ. It is educational and not medical advice. Whether tirzepatide suits you, under either name, is a decision for a licensed provider.

Why one molecule has two brand names

Drug companies often sell one molecule under separate brands when it is approved for different conditions. Each approval comes with its own label, its own dosing guidance, and its own place in insurance systems.

Mounjaro is approved to improve blood sugar control in adults and children 10 and older with type 2 diabetes [1]. In August 2026, the FDA added a second use: lowering the risk of major cardiovascular events in adults with type 2 diabetes at high risk [3].

Zepbound is approved for chronic weight management, alongside diet and exercise, in adults with obesity or with overweight plus a weight-related condition [2]. It is also approved to treat moderate to severe obstructive sleep apnea in adults with obesity, the first medication approved for that condition [2, 4].

So the label tells you the intended patient. Mounjaro's approved indications center on type 2 diabetes and associated cardiovascular risk, whereas Zepbound's approved indications center on chronic weight management and obesity-associated obstructive sleep apnea. Prescribing Mounjaro for weight loss in someone without type 2 diabetes is off-label use. Mounjaro came first, approved in 2022 [1]. Zepbound followed in 2023 [2], after a separate set of trials tested tirzepatide specifically for weight management.

Mounjaro vs Zepbound: what is the same and what is different

Because the active ingredient is identical, much of the practical experience is the same.

What matches:

• Active ingredient: tirzepatide, which activates both the GLP-1 and GIP receptors [1, 2]
• Schedule: one injection, once a week
• Dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg [1, 2]
• Starting dose and steps: both labels start at 2.5 mg and increase in 2.5 mg steps, at least four weeks apart [1, 2]
• Safety warnings: both carry the same boxed warning about thyroid C-cell tumors seen in rodents [1, 2]

What differs:

• Approved uses: diabetes and cardiovascular risk for Mounjaro; weight management and sleep apnea for Zepbound [1, 2]
• Who it is labeled for: Mounjaro's diabetes indication includes children 10 and older, while Zepbound is labeled for adults [1, 2]
• Maintenance dosing guidance: the Zepbound label lists specific maintenance doses for weight management and for sleep apnea, while the Mounjaro label is built around blood sugar goals [1, 2]
• Insurance and pricing: covered in the next two sections

Both brands now come in more than one device. In February 2026, the FDA approved a four-dose KwikPen for Zepbound, which holds a month of weekly doses in one pen [5]. Mounjaro's label also lists a KwikPen alongside single-dose pens and vials [1]. Single-dose pens and the multi-dose presentations use slightly different inactive ingredients, so the label lists them separately [1]. Not every presentation is stocked everywhere, and a provider or pharmacist can confirm what is available. For how dose increases work in practice, see our semaglutide and tirzepatide dosing guide.

Side effects: one molecule, nearly the same warnings

Because both brands contain tirzepatide, their labels describe largely the same side effects and warnings [1, 2]. The most common side effects are digestive, including nausea, diarrhea, vomiting, constipation, and decreased appetite [1, 2].

The labels also warn about pancreatitis, diabetic retinopathy, gallbladder problems, and severe digestive reactions. Other warnings cover low blood sugar when combined with insulin or a sulfonylurea, kidney injury linked to dehydration, and serious allergic reactions [1, 2]. Both labels flag aspiration risk during anesthesia or deep sedation, so tell any surgical team you take tirzepatide [1, 2].

Neither brand should be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2 [1, 2]. Both can also make oral birth control less effective. The labels advise a non-oral or backup method for four weeks after starting and after each dose increase [1, 2]. Earlier Zepbound labeling included a warning regarding suicidal thoughts and behavior. In January 2026, however, FDA announced that a comprehensive review found no increased risk of suicidal ideation or behavior with GLP-1 receptor agonists and requested removal of this warning from Zepbound and other affected weight-management GLP-1 medications [6].

Like any prescription medication, tirzepatide carries risks and possible side effects your provider will review with you, whichever brand name is on the box. These are not comprehensive lists of risks or contraindications; patients should review the prescribing information and discuss their medical history with their clinician.

Insurance: the main practical difference

In the Zepbound vs Mounjaro comparison, coverage is where the two brands split. If the molecule is the same, why can coverage differ so much? Because insurers decide coverage by what a drug is prescribed for, not only by what it contains.

Mounjaro usually falls under a plan's diabetes benefit. Plans commonly cover diabetes medications, though many require prior authorization and a confirmed type 2 diabetes diagnosis. Without that diagnosis, a plan may decline to cover Mounjaro.

Zepbound usually falls under a weight-management benefit, which many employer plans exclude entirely. Where it is covered, plans often require prior authorization and documentation of weight-related health criteria. A sleep apnea diagnosis can change how some plans review it, since that is a separate approved use.

Medicare has a newer wrinkle. Medicare historically could not cover drugs used only for weight loss. Since July 1, 2026, a temporary program called the Medicare GLP-1 Bridge has changed that for some people. Certain people enrolled in Medicare Part D may be eligible for some weight-management drugs, including the Zepbound KwikPen, at a $50 monthly copay [7]. It runs through the end of 2027, and the copay does not count toward Part D deductibles or the annual out-of-pocket cap [7]. The program operates outside the standard Part D benefit. A provider has to send a prescription that meets the program's criteria [7].

Coverage rules vary widely by plan. The quickest way to know where you stand is to ask your insurer how each brand is covered, or to have your provider's office check.

Cost and savings programs

Prices change often, so treat these as approximate and confirm on the manufacturer's site. These are manufacturer prices, not Luvo prices.

• List price: both brands run roughly $1,000 to $1,100 a month before insurance or discounts. Mounjaro's list price is about $1,112 [8].
• Mounjaro self-pay: Lilly sells Mounjaro directly starting at $499 a month and offers a savings card for people with commercial insurance [8].
• Zepbound self-pay: through LillyDirect, the KwikPen and single-dose vials start at $299 a month for 2.5 mg and $399 for 5 mg. Doses from 7.5 mg to 15 mg are $449 a month when refilled within 45 days [9]. Higher prices apply if a refill comes later, and the program cannot be combined with insurance [9].

The practical takeaway is counterintuitive. For someone paying out of pocket, the weight-management brand of tirzepatide can cost less than the diabetes brand. Insurance status still matters more than any of these numbers.

What about compounded tirzepatide?

Compounded tirzepatide is not FDA-approved and is subject to federal and state compounding requirements. FDA recommends use of an FDA-approved drug when it is available and appropriate for the patient. Because the tirzepatide shortage has been resolved, federal law generally restricts pharmacies and outsourcing facilities from routinely producing compounded products that are essentially copies of commercially available FDA-approved tirzepatide products. In limited circumstances, patient-specific compounding may be permissible when applicable legal requirements are satisfied and a patient's clinical needs cannot appropriately be met by an available FDA-approved product. The FDA does not evaluate compounded drugs for safety, effectiveness, or quality [10]. A compounded formulation is not Mounjaro or Zepbound, and it is not a generic version of either. The trial results in this article did not come from compounded products. Data from clinical trials of Mounjaro and Zepbound should not be assumed to establish the safety, effectiveness, quality, potency, or bioequivalence of a compounded tirzepatide product.

The rules around compounded GLP-1 medications have been changing, so availability can shift. A provider can explain current options and their risks. For more, see the important safety information for compounded tirzepatide.

Common questions

Can I switch between Mounjaro and Zepbound?
Switching is possible, but it goes through your provider. A new brand means a new prescription, and often a new insurance review. Because the dose strengths match, your provider will decide whether to continue at your current dose or adjust it.

Is one stronger?
At an equivalent dose, neither brand is considered inherently more potent: both contain tirzepatide, and the available dose strengths overlap [1, 2]. Differences in trial results should not be interpreted as evidence that one brand is intrinsically stronger because the studies enrolled different patient populations and used different study designs. In SURMOUNT-1, adults with obesity but without diabetes lost an average of 15.0% to 20.9% of body weight over 72 weeks, depending on dose [11]. In SURMOUNT-2, adults with obesity and type 2 diabetes lost 12.8% to 14.7% [12]. Individual results vary.

Why does insurance treat them differently?
Coverage commonly differs because insurers consider the FDA-approved indication, the patient's diagnosis, the plan's formulary and benefit design, and applicable utilization-management requirements. Mounjaro sits under diabetes coverage, which most plans include. Zepbound sits under weight-management coverage, which many plans exclude or restrict with prior authorization.

Which one do providers prescribe for weight loss?
For weight management on its own, Zepbound is the brand with that FDA approval [2]. For someone who also has type 2 diabetes, a provider may choose Mounjaro. The choice depends on your diagnoses, history, coverage, and cost.

Next steps

If any of this sounds like what you are dealing with, the next step is a conversation with a licensed provider who can review your history and decide whether treatment makes sense for you. Nothing is prescribed or shipped without that review. Any medication preference you indicate is only a starting point for discussion. A licensed clinician will independently determine whether prescription treatment is medically appropriate and, if so, which medication and dose are appropriate based on your health history and clinical evaluation.

Explore Luvo's Weight Loss Program.